Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking
surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but
most often a recurrence occurred in the first 18 months. Early recurrence signs
chemoresistance and palliative treatment. The study of predictive clinical or biological
factors is required to adapt therapeutic and develop new treatments.